FIELD: medicine, analytical chemistry.
SUBSTANCE: invention relates to a method for quantitative determination of soluble fibrin in a blood sample. Sample is contacted with plasminogen activating agent showing high specificity to soluble fibrin (PA-Fb sp) and the content of soluble fibrin in sample is determined by measuring difference between content of fibrin degradation products representing D-dimers formed after degradation of soluble fibrin by using PA-Fb sp and the basic content of fibrin degradation products determined in the parent sample before its contact with PA-Fb sp. Also, invention relates to a set for realization of the claimed method, reagent used in the claimed method and a set as positive control, using plasminogen activating agent of high specificity to soluble fibrin in the claimed method and using activation of the coagulation process and estimation of effectiveness of anticoagulant therapy. The claimed method allows controlling the coagulation of activation process, evaluating effectiveness of anticoagulant therapy and assaying whether coagulation activation occurs again after ceasing therapy.
EFFECT: improved assay method.
21 cl, 6 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| DIAGNOSTICS OF THROMBOEMBOLIC VEIN DISEASES BY DETERMINATION OF CONTENT OF D-DIMERS AND SOLUBLE FIBRIN | 2007 |
|
RU2475760C2 |
| DETERMINING OF CIRCULATING THROMBIN IN COMPLEMENT ACTIVATION TEST | 2019 |
|
RU2709341C1 |
| IMMUNOASSAY OF SOLUBLE FIBRIN POLYMERS | 1994 |
|
RU2173347C2 |
| METHOD OF DETERMINING THROMBIN COMPLEMENTARITY SYSTEM ACTIVATION PATHWAY | 2019 |
|
RU2717946C1 |
| METHOD FOR DETERMINING HEMOSTASIS CRITERIA FOR PREDICTING UNFAVORABLE SEPSIS OUTCOME IN ACUTE MYELOBLASTOSIS CASES | 2006 |
|
RU2320996C1 |
| USE OF ACTIVATED BLOOD COAGULATION FACTOR VII FOR TREATMENT OF EXTENSIVE BLOODINGS CAUSED BY THROMBOLYTIC THERAPY | 2001 |
|
RU2286796C2 |
| METHOD FOR PREDICTING PULMONARY ARTERIAL EMBOLIZATION IN ONCOLOGY PATIENTS WITH LOWER EXTREMITY PHLEBOTHROMBOSIS | 2016 |
|
RU2664448C2 |
| RECOMBINANT POLYPEPTIDE WITH HUMAN PLASMINOGEN PROPERTIES TO CONVERT INTO PLASMIN IF ACTIVATED WHICH CATALYSES FIBRIN SPLITTING, DNA FRAGMENT CODING POLYPEPTIDE, RECOMBINANT PLASMID DNA FOR POLYPEPTIDE EXPRESSION AND TRANSFORMED Escherichia coli CELL - POLYPEPTIDE PRODUCER | 2009 |
|
RU2432396C2 |
| REAGENT KIT FOR DIAGNOSING DEGREE OF NEUROINFLAMMATION | 2018 |
|
RU2698206C1 |
| METHOD FOR PRODUCING AUTOLOGOUS FIBRIN WITH CONTROLLED FIBRINOGEN CONTENT WITHOUT USING EXOGENOUS THROMBIN | 2020 |
|
RU2758260C1 |
